Using MRI to detect muscle-invasive bladder cancer
Knowledge-guided Causal Diagnostic Network for the Detection of Muscle-invasive Bladder Cancer With Single T2-weighted Imaging
The First Affiliated Hospital with Nanjing Medical University · NCT06362330
This study is testing a new MRI method to see if it can better detect muscle-invasive bladder cancer before surgery for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University (other) |
| Locations | 1 site (Nanjing) |
| Trial ID | NCT06362330 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the preoperative detection of muscle-invasive bladder cancer using multiparametric magnetic resonance imaging (MRI). Researchers collected data from patients who underwent bladder MRI at three centers over a ten-year period. They developed a knowledge-guided causal diagnostic network that combines advanced segmentation techniques and self-supervised learning to enhance the accuracy of cancer staging. The model was trained at one center and tested independently at others to validate its effectiveness against traditional methods.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed urothelial carcinoma of the bladder who have undergone a standard contrast-enhanced 3.0T mpMRI before surgery.
Not a fit: Patients who have not undergone surgical interventions or have inadequate image quality or pathology for analysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate preoperative diagnoses of muscle-invasive bladder cancer, potentially improving treatment outcomes.
How similar studies have performed: Other studies utilizing advanced imaging techniques and AI for cancer detection have shown promising results, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Urothelial carcinoma of the bladder confirmed by final histopathology ②Received a standard contrast-enhanced 3.0T mpMRI before surgery ③All tumors within patients included were resected and received pathologic examination separately Exclusion Criteria: ①Absence of surgical interventions ②With inadequate image quality or with inadequate pathology for analysis
Where this trial is running
Nanjing
- Yu-Dong Zhang — Nanjing, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Muscle-invasive Bladder Cancer, Artificial Intelligence